# US 2011/0256058 A1 · Novel Peptides and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0256058 A1
- Document ID: US20110256058A1
- Status: Published application
- Kind: A1
- Application number: 12/738,619
- Filed: 2008-10-17
- Published: 2011-10-20
- Earliest claimed: 2007-10-17
- Assignees: University of Southern California
- Inventors: Mehran Neshat
- Web page: https://patentgrep.com/patent/US20110256058A1

## CPC

- A61K 49/00: Preparations for testing in vivo
- A61K 49/0021: {the fluorescent group being a small organic molecule}
- A61K 49/0041: {Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- C07K 7/64: Cyclic peptides containing only normal peptide links
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a peptide of 8-50 amino acids comprising the sequence of KAHKKRAD or KARKKHAD, or a cyclic peptide of 8-50 amino acids comprising the sequence of HKKR or RKKH. Also disclosed are methods of using the peptide for detecting, monitoring, or treating cancer.

## Claims

### Claim 1

A peptide comprising the sequence of KAHKKRAD (SEQ ID NO:1) or KARKKHAD (SEQ ID NO:2), wherein the length of the peptide is in the range of 8-50 amino acids.

### Claim 2

A cyclic peptide comprising the sequence of HKKR (SEQ ID NO:3), wherein the length of the peptide is in the range of 8-50 amino acids.

### Claim 3 (depends on 1)

The peptide of claim 1, wherein the length of the peptide is in the range of 8-20 amino acids.

### Claim 4 (depends on 3)

The peptide of claim 3, wherein the length of the peptide is in the range of 8-12 amino acids.

### Claim 5 (depends on 1)

The peptide of claim 1, wherein the peptide is linear or cyclic.

### Claim 6 (depends on 2)

The peptide of claim 2, wherein the peptide is cyclized via a link between a side chain and the backbone.

### Claim 7 (depends on 2)

The peptide of claim 2, wherein the peptide is cyclized via a link between two reactive groups on the backbone.

### Claim 8 (depends on 1)

The peptide of claim 1, wherein the peptide is detectably labeled.

### Claim 9 (depends on 1)

The peptide of claim 1, wherein the peptide is linked to another molecule.

### Claim 10 (depends on 9)

The peptide of claim 9, wherein the molecule is an imaging or therapeutic agent.

### Claim 11 (depends on 1)

The peptide of claim 1, wherein the peptide is cyclized via a link between the side chain of D and the backbone of K.

### Claim 12 (depends on 1)

A composition comprising a pharmaceutically acceptable carrier and the peptide of claim 1.

### Claim 13 (depends on 1, 2)

A method of binding the peptide of claim 1 to an aI domain, comprising contacting the peptide of claim 1 or 2 with an aI domain, thereby allowing binding of the peptide to the aI domain.

### Claim 14 (depends on 13)

The method of claim 13, wherein the aI domain is in α2, α1, α10, or α11.

### Claim 15 (depends on 13)

The method of claim 13, wherein the aI domain is in α2β1.

### Claim 16 (depends on 13)

The method of claim 13, wherein the aI domain is on or in a cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cell is a cancer cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cancer is breast or ovarian cancer.

### Claim 19 (depends on 16)

The method of claim 16, wherein the cell is in a subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the subject is mouse.

### Claim 21 (depends on 1)

A method of detecting cells expressing an aI domain, comprising:
contacting the peptide of claim 1 with a cell; and
detecting binding of the peptide to an aI domain on or in the cell.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cell is a cancer cell.

### Claim 23 (depends on 22)

The method of claim 22, wherein the cancer is breast or ovarian cancer.

### Claim 24 (depends on 21)

The method of claim 21, wherein the cell is in a subject.

### Claim 25 (depends on 24)

The method of claim 24, wherein the subject is mouse.

### Claim 26 (depends on 24)

The method of claim 24, further comprising isolating the cell from the subject.

### Claim 27 (depends on 21)

The method of claim 21, wherein the binding of the peptide to the aI domain is detected by imaging.

### Claim 28 (depends on 21)

The method of claim 21, wherein the binding of the peptide to the aI domain is detected by detecting the peptide on or in the cell.

### Claim 29 (depends on 21)

The method of claim 21, wherein the binding of the peptide to the aI domain, if at a level higher than that for a normal control cell, indicates that the cell is a cancer cell or contributes to cancer progression.

### Claim 30 (depends on 1)

A method of modulating the biological function or localization of a molecule having an aI domain, comprising contacting the peptide of claim 1 with a molecule having an aI domain, thereby modulating the biological function or localization of the molecule.

### Claim 31 (depends on 30)

The method of claim 30, wherein the molecule is on or in a cell.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cell is a cancer cell.

### Claim 33 (depends on 32)

The method of claim 32, wherein the cancer is breast or ovarian cancer.

### Claim 34 (depends on 31)

The method of claim 31, wherein the cell is in a subject.

### Claim 35 (depends on 34)

The method of claim 34, wherein the subject is mouse.

### Claim 36 (depends on 1)

A method of monitoring cancer status in a subject, comprising:
introducing cancer cells into a subject;
allowing the cancer to progress at the primary site or to metastasis in the subject;
administering the peptide of claim 1 to the subject; and
detecting the peptide on or in the cancer cells, thereby monitoring the status of the cancer in the subject.

### Claim 37 (depends on 36)

The method of claim 36, wherein the subject is mouse.

### Claim 38 (depends on 36)

The method of claim 36, wherein the cancer is breast or ovarian cancer.

### Claim 39 (depends on 36)

The method of claim 36, wherein the peptide is detected by imaging.

### Claim 40

A cell of subline MDA-MB-231-MBF1C-Luc, MDA-MB-231-MBF1C-Luc-GFP, or MDA-MB-231-MM-Luc.

### Claim 41 (depends on 1)

A method of monitoring cancer status in a subject, comprising:
administering the peptide of claim 1 to a subject having cancer cells; and
detecting the peptide on or in the cancer cells, thereby monitoring the status of the cancer in the subject.
